Shots:
- The EC has granted conditional approval for Jemperli in women with dMMR/ MSI-H endometrial cancer that has progressed on or following prior treatment with a Pt.- containing regimen
- AnaptysBio has received $10M as milestones upon the EC’s approval and will receive $35M as regulatory milestones in the US & EU, $165M as sales milestones following achievement of annual sales revenues with royalties range from 8% to 25% of global sales
- GSK and AnaptysBio continue to develop Abs including cobolimab and GSK4074386. AnaptysBio will receive milestones for each of the first two indications of Abs and is eligible to receive ~$1.1B in milestones with royalties ranging from 4% to 8% on global net sales of Abs and 1% of GSK’s global sales of Zejula
Click here to read full press release/ article | Ref: Globe Newswire | Image: Linkedin
The post GSK’s Jemperli (dostarlimab) Receives the EC’s Approval for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer first appeared on PharmaShots.
